<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="preparation" /><meta name="keywords" content="Tysabri; Natalizumab" /><meta name="IX" content="Tysabri; Natalizumab" /><title>Tysabri®: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5725-tysabri.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5725-tysabri.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5725-tysabri.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5590-drugs-affecting-the-immune-response.htm">8.2 Drugs affecting the immune response</a> &gt; <a href="PHP5665-other-immunomodulating-drugs.htm">8.2.4 Other immunomodulating drugs</a> &gt; <a href="PHP5720-natalizumab.htm">Natalizumab</a> &gt; <a href="PHP5724-natalizumab.htm">NATALIZUMAB</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5720-natalizumab.htm" title="Previous: Natalizumab">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5728-sex-hormones-and-hormone-antagonists-in-malignant-disease.htm" title="Next: 8.3 Sex hormones and hormone antagonists in malignant disease">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a304030.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Natalizumab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Miscellaneous Therapeutic Agents 92:00 &gt; Biologic Response Modifiers 92:20</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/20178-m.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Natalizumab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: N &gt; Interactions of Natalizumab</p></div></li></ul><ul><li><h3>British National Formulary (3)</h3></li><li><a href="PHP5720-natalizumab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Natalizumab</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.4 Other immunomodulating drugs</p></div></li><li><a href="PHP5724-natalizumab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">NATALIZUMAB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.4 Other immunomodulating drugs &gt; Natalizumab</p></div></li><li><a href="PHP9436-natalizumab.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Natalizumab</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; Appendix 4 Intravenous additives &gt; Use of table &gt; Table of drugs given by intravenous infusion</p></div></li></ul><ul><li><h3>Injectable Drugs Guide</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/n03-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Natalizumab</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; N</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/20178-m.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Natalizumab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Miscellaneous Drugs and Other Substances &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/06426.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Natalizumab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; N &gt; NA</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-N14.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Natalizumab</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; N</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E2E3E0R0D2248.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Natalizumab</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; N</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1>NATALIZUMAB</h1><?highlighter on?><div id="pC" class="jN"><div class="cL"><div class="cE"><h2 class="cN">Indications </h2> <p class="cT">see <a title="monograph-family: Natalizumab" href="PHP5720-natalizumab.htm">notes above </a></p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Cautions </h2> <p class="cT">see <a title="monograph-family: Natalizumab" href="PHP5720-natalizumab.htm">notes above</a> and consult product literature; prior treatment with immunosuppressants (increased risk of progressive multifocal leukoencephalopathy); monitor liver function (see below)</p></div> <div class="cG"><div class="cE"><h3 class="cT">Liver toxicity</h3> <p class="cT">Liver dysfunction reported; advise patients to seek immediate medical attention if symptoms such as jaundice or dark urine develop; discontinue treatment if significant liver injury occurs</p></div></div> <div class="cG"><div class="cE"><h3 class="cT">Progressive multifocal leucoencephalopathy (PML)</h3> <p class="cT">Patients should be informed about the risks of PML before starting treatment with natalizumab and again after 2 years; they should be given an alert card which includes information about the symptoms of PML (see also <a title="BNF:monograph-family: Natalizumab" href="PHP5720-natalizumab.htm">notes above</a>)</p></div></div> <div class="cG"><div class="cE"><h3 class="cT">Hypersensitivity reactions</h3> <p class="cT">Patients should be told the importance of uninterrupted dosing, particularly in the early months of treatment (intermittent therapy may increase risk of sensitisation)</p></div></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Contra-indications </h2> <p class="cT">progressive multifocal leucoencephalopathy; active infection (see notes above); concurrent use of interferon beta or glatiramer acetate; immunosuppression; active malignancies (except cutaneous basal cell carcinoma)</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Pregnancy </h2> <p class="cT">avoid unless essential—toxicity in <em>animal</em> studies</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Breast-feeding </h2> <p class="cT">present in milk in <em>animal</em> studies—avoid</p></div> </div> <div class="cL"><div class="cE"><h2 class="cN">Side-effects </h2> <p class="cT">see <a title="monograph-family: Natalizumab" href="PHP5720-natalizumab.htm">notes above</a>; also urinary-tract infection, nasopharyngitis, autoantibodies, and arthralgia; <em>less commonly</em> hypersensitivity reactions (see above); liver toxicity also reported</p></div> </div> <div class="cL"><h2 class="cM">Dose</h2><div class="cR"><ul><li><p><span class="cK">By intravenous infusion</span>, <span class="cP">adult</span> over 18 years, 300 mg once every 4 weeks; discontinue if no response after 6 months</p></li> </ul></div></div> </div><div id="pS"><p>Sub-sections</p><div id="PHP5725-tysabri" style="margin: 0 0 0 20px;"><h1 class="title">Tysabri® <span>(<a href="PHP10005-index-of-manufacturers.htm#PHP10063">Biogen</a>)</span><span> <a title="Report adverse reaction(s)" href="PHP10518-yellow-card-scheme.htm"><img class="cD" src="images/blacktri_s.png" alt="Report adverse reaction(s)" /></a> <img src="images/pom_l.png" alt="Prescription only medicine" /></span></h1><div class="cU"><p><strong>Concentrate for intravenous infusion</strong>, natalizumab 20 mg/mL, net price 15-mL vial = £1130.00. Counselling, liver toxicity, progressive multifocal leucoencephalopathy, and hypersensitivity, patient alert card </p><p class="cR"><span class="cAD">Electrolytes </span>Na<sup>+</sup> 2.3 mmol/vial</p></div></div></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5720-natalizumab.htm">Previous: Natalizumab</a> | <a class="top" href="PHP5725-tysabri.htm#">Top</a> | <a accesskey="]" href="PHP5728-sex-hormones-and-hormone-antagonists-in-malignant-disease.htm">Next: 8.3 Sex hormones and hormone antagonists in malignant disease</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>